Telcon RF Pharmaceutical KRX:200230KOSDAQ
텔콘RF제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days1
Articles tracked4since Sep 11
In Q2 2026, Telcon RF Pharmaceutical reported revenue of ₩28.9bn, up 188.5% year on year, and an operating loss of ₩806m. Telcon RF Pharmaceutical (텔콘RF제약) appeared in 2 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 26 with 2 articles. The most common catalyst was contracts & orders (2).
Filing signals Revenue +30% Supply contract Screener
Telcon RF Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩28.9bn | +188.5% | −₩806m margin −2.8% | −₩22.3bn |
| Q1 2026 | ₩9.7bn | -2.8% | −₩1.4bn margin −14.7% | −₩11.5bn |
| Q4 2025 derived | ₩13.3bn | -3.7% | ₩2.6bn margin 19.7% | ₩9.8bn |
| Q3 2025 | ₩9.8bn | +37.2% | −₩9m margin −0.1% | −₩4.8bn |
| Q2 2025 | ₩10.0bn | +13.6% | −₩397m margin −4.0% | −₩1.8bn |
| Q1 2025 | ₩10.0bn | +24.2% | −₩1.5bn margin −15.0% | −₩14.6bn |
| Q4 2024 derived | ₩13.8bn | +7.1% | ₩3.1bn margin 22.6% | −₩12.2bn |
| Q3 2024 | ₩7.2bn | -19.0% | −₩1.2bn margin −17.3% | ₩3.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Telcon RF Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2